Shares of Japanese drugmaker Eisai Co. gained after US regulators approved the first blood test to help diagnose Alzheimer’s disease, fueling expectations of an uptick in demand for drugs used to treat the illness.
Eisai Shares Rise as New Alzheimer’s Test Seen Helping Sales
